Elicio Therapeutics (ELTX) Non Operating Interest Expenses (2022 - 2026)

Elicio Therapeutics (ELTX) has reported Non Operating Interest Expenses for 5 consecutive years, with $410000.0 the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non Operating Interest Expenses rose 111.34% year-over-year to $410000.0; the trailing twelve-month figure through Jun 2026 stood at $1.6 million (up 113.23% YoY), and the FY2025 full-year result was $1.1 million, up 149.01% from the prior year.
• Non Operating Interest Expenses rose to $410000.0 in Q2 2026 per ELTX's latest filing, from $407000.0 in the prior quarter.
• Across five years, Non Operating Interest Expenses topped out at $1.1 million in Q3 2022 and bottomed at $1000.0 in Q3 2023.
• Historically, Non Operating Interest Expenses has averaged $335411.8 across 5 years, with a median of $234000.0 in 2024.
• The sharpest annual moves came in 2023 and 2024: Non Operating Interest Expenses slumped 99.91% in 2023, then jumped 13600.0% in 2024.
• Over 5 years, Non Operating Interest Expenses stood at $92000.0 in 2022, then plunged by 97.83% to $2000.0 in 2023, then soared by 11600.0% to $234000.0 in 2024, then surged by 44.02% to $337000.0 in 2025, then advanced by 21.66% to $410000.0 in 2026.
• According to Business Quant data, Non Operating Interest Expenses over the past three periods registered $410000.0, $407000.0, and $337000.0 for Q2 2026, Q1 2026, and Q4 2025 respectively.